Osimertinib in Untreated - The New England Journal of Medicine
Nov 18, 2017 · The results of the FLAURA trial show that in patients with previously untreated EGFR mutation–positive advanced NSCLC, osimertinib treatment resulted in significantly longer progression-free ...
Overall Survival with Osimertinib in Untreated,
Nov 21, 2019 · In the FLAURA trial, a double-blind, randomized phase 3 trial involving untreated patients with EGFR mutation–positive advanced NSCLC, those who received osimertinib had significantly longer ...
Osimertinib with or without Chemotherapy in
Nov 8, 2023 · Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance mutations. Evidence...
FDA approves osimertinib with chemotherapy for EGFR-mutated …
On February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or...
FLAURA2 Trial Osimertinib Plus Chemotherapy Improves ... - ASCO …
Oct 10, 2023 · FLAURA2 was designed to evaluate whether osimertinib plus standard platinum-based chemotherapy would lead to superior outcomes compared with osimertinib monotherapy in patients with advanced EGFR-mutated NSCLC. Study Details.
Osimertinib in Advanced Lung Cancer with EGFR Mutations
Dec 12, 2019 · The cancer drug osimertinib (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations, updated results from the FLAURA clinical trial show. People treated with osimertinib lived longer than those treated with earlier-generation EGFR-targeted therapies.
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Read about the FLAURA study design & efficacy of TAGRISSO® (osimertinib) as a first-line treatment for patients with metastatic EGFRm NSCLC
FLAURA2 Results Demonstrate Osimertinib Plus Chemotherapy
According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs. The study enrolled 557 patients and randomized them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy.
First-line osimertinib for patients with EGFR-mutated advanced …
The FLAURA trial demonstrated improved overall survival (OS) with first-line osimertinib for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). We studied the efficacy and safety of osimertinib in a cohort treated during the coronavirus disease 2019 (COVID-19) pandemic.
Final FLAURA Results Demonstrate Overall Survival Benefit
Sep 29, 2019 · First-line treatment with osimertinib provided improved overall survival (OS) over standard treatment with a comparator tyrosine kinase inhibitor (TKI) in patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer (NSCLC).